The 2026 EAU guideline update for non-muscle-invasive bladder cancer adds tables on risk and prognostic factors, treatment options for BCG-unresponsive tumours and urinary markers, plus new sections on adding immune checkpoint inhibitors to BCG and on de-intensification.
Guideline
Gontero et al. EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS) - A Summary of the 2026 Guidelines Update